Article in Journal of leukocyte biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Jessica N FildermanDepartment of Immunology, University of Pittsburgh School of Medicine, W1110 Thomas E. Starzl Biomedical Sciences Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Jason J LukeDepartment of Medicine, University of Pittsburgh School of Medicine, 1.27C Research Pavilion, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA 15213, USA.
Walter J StorkusDepartment of Immunology, University of Pittsburgh School of Medicine, W1110 Thomas E. Starzl Biomedical Sciences Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
University of Pittsburgh · USUPMC Hillman Cancer Center · US
Funding
VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
Project 5: Microenvironment manipulation using anti-angiogenics to improve immunotherapy in melanomaP50CA254865 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, HONG · 2021 to 2025
$10.4M
Targeting the Chemokine System to Sensitize Tumors to ImmunotherapyP01CA234212 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KALINSKI, PAWEL · 2020 to 2024
$10.1M
NCI ET-CTN with Phase i Emphasis at UPCIUM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani · 2014 to 2026
$9.1M
Immune Exclusion in Cancer ImmunotherapyR01DE031729 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Riyue Bao, Dan Paul Zandberg · 2022 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Platelet STING agonism and venous thrombosis: translational implications for improved disease outcomes. · full record | OpenQuestion